[1]任 翔,过轶斌,张立元.罗沙司他对重组人促红细胞生成素疗效不佳血液透析肾性贫血患者血生化、铁代谢和钙磷代谢的影响[J].陕西医学杂志,2023,52(7):902-905，915.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.029]
　REN Xiang,GUO Yibin,ZHANG Liyuan.Effect of roxadustat on blood biochemistry,iron metabolism and calcium-phosphorus metabolism in patients undergoing hemodialysis for renal anemia inadequately controlled by rHuEPO[J].,2023,52(7):902-905，915.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.029]
点击复制

罗沙司他对重组人促红细胞生成素疗效不佳血液透析肾性贫血患者血生化、铁代谢和钙磷代谢的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年7期
页码:
902-905，915
栏目:
药物与临床
出版日期:
2023-07-05

文章信息/Info

Title:
Effect of roxadustat on blood biochemistry,iron metabolism and calcium-phosphorus metabolism in patients undergoing hemodialysis for renal anemia inadequately controlled by rHuEPO
作者:
任 翔; 过轶斌; 张立元
(徐州医科大学附属连云港医院肾内科,江苏 连云港 222000)
Author(s):
REN Xiang; GUO Yibin; ZHANG Liyuan
(Department of Nephrology,Lianyungang Hospital Affiliated to Xuzhou Medical University,Lianyungang 222000,China)
关键词:
罗沙司他;  重组人促红细胞生成素;  血液透析;  肾性贫血;  铁代谢;  钙磷代谢
Keywords:
Roxadustat;  Recombinant human erythropoietin;  Hemodialysis;  Renal anemia;  Iron metabolism;  Calcium-phosphorus metabolism
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7377.2023.07.029
文献标志码:
A
摘要:
目的:探讨罗沙司他对重组人促红细胞生成素(rHuEPO)疗效不佳血液透析肾性贫血患者血生化、铁代谢和钙磷代谢的影响。方法: 选取既往使用rHuEPO治疗3个月以上疗效不佳的血液透析肾性贫血患者100例,以随机数表法将其纳入观察组(n=50)与对照组(n=50)。对照组采用rHuEPO联合琥珀酸亚铁缓释片治疗,观察组则采用罗沙司他联合琥珀酸亚铁缓释片治疗,两组均持续治疗3个月,观察两组治疗前后血生化[血红蛋白(Hb)、红细胞计数(RBC)、血细胞比容(Hct)]、铁代谢[血清铁蛋白(SF)、总铁结合力(TIBC)、转铁蛋白饱和度(TSAT)、不饱和铁结合力(UIBC)]、钙磷代谢指标及炎性因子[C-反应蛋白(CRP)、白介素6(IL-6)]水平,并统计不良反应的发生情况。结果: 治疗后两组患者的Hb、RBC、Hct、血清铁(SI)及TIBC水平较治疗前增加,且观察组较对照组高(均P<0.05),同时UIBC水平较治疗前减少,且观察组较对照组低(P<0.05)。治疗后两组血钙、血磷水平均较治疗前减少,两组间比较差异没有统计学意义(均P>0.05)。治疗后两组血清CRP及IL-6水平均较治疗前减少,且观察组较对照组低(均P<0.05)。此外两组不良反应总发生率之间的比较差异没有统计学意义(P>0.05)。结论: 罗沙司他能有效改善对rHuEPO疗效不佳血液透析肾性贫血患者的贫血程度,同时有助于改善患者机体铁代谢及炎症反应,且不良反应发生率低。
Abstract:
Objective:To investigate the effect of roxadustat on blood biochemistry,iron metabolism and calcium-phosphorus metabolism in patients undergoing hemodialysis for renal anemia inadequately controlled by recombinant human erythropoietin(rHuEPO).Methods:One hundred patients undergoing hemodialysis for renal anemia inadequately controlled by rHuEPO for more than 3 months were selected and divided into the observation group(50 cases)and the control group(50 cases)by random number table method.The control group was treated with rHuEPO combined with ferrous succinate sustained release tablets,while the observation group was treated with roxadustat combined with ferrous succinate sustained release tablets.Both groups were continuously treated for 3 months.Blood biochemical parameters [hemoglobin(Hb),red blood cell count(RBC)and hematocrit(Hct)],iron metabolism [serum ferritin(SF),total iron binding capacity(TIBC),transferrin saturation(TSAT)and unsaturated iron binding capacity(UIBC)],calcium-phosphorus metabolism indicators and inflammatory factors [C-reactive protein(CRP)and interleukin 6(IL-6)]in the two groups were observed before and after treatment.The incidence rates of adverse reactions were recorded.Results:After treatment,the levels of Hb,RBC,Hct,Serum iron(SI)and TIBC in the two groups increased,and the levels of those in the observation group were higher than those in the control group(all P<0.05); the level of UIBC decreased in comparison with that before treatment,and UIBC level in the observation group was lower than that in the control group(all P<0.05).After treatment,the levels of blood calcium and phosphorus in the two groups were lower than those before treatment(all P<0.05),but there was no significant difference between groups(all P>0.05).After treatment,serum CRP and IL-6 levels in the two groups were lower than those before treatment(all P<0.05),and the levels of those in the observation group were lower than those in the control group(all P<0.05).There was no significant difference in the total incidence of adverse reactions between groups(P>0.05).Conclusion:Roxadustat can effectively improve the degree of anemia in patients undergoing hemodialysis for renal anemia inadequately controlled by rHuEPO,and help improve iron metabolism and inflammatory response,with a low incidence of adverse reactions.

参考文献/References:

[1] 王 冰.高通量血液透析对终末期肾衰患者营养状况及肾性贫血状况的影响[J].陕西医学杂志,2019,48(6):766-769.
[2] Yang Q,Wang X.A case report of rhabdomyolysis caused by the use of roxadustat in the treatment of caused by renal anemia[J].Int J Clin Pract,2021,75(6):e14011.
[3] Chopard R,Piazza G,Falvo N,et al.An original risk score to predict early major bleeding in acute Pulmonary Embolism:The Syncope,Anemia,Renal Dysfunction(PE-SARD)bleeding score[J].Chest,2021,160(5):1832-1843.
[4] 李家青,杨 晴,袁敦禄,等.罗沙司他治疗血液透析患者肾性贫血的有效性和安全性Meta分析[J].中国全科医学,2023,26(6):704-710.
[5] Wang H,Chen M,Zhang T,et al.Recombinant human erythropoietin upregulates PPARγ through the PI3K/Akt pathway to protect neurons in ratssubjected to oxidative stress[J].Eur J Neurosci,2022,56(3):4045-4059.
[6] 李 璐,尹忠诚,冯锦红,等.罗沙司他代替重组人红细胞生成素治疗维持性透析患者肾性贫血的效果观察[J].中国血液净化,2022,21(8):564-568.
[7] Cox HD,Miller GD,Manandhar A,et al.Tracking immature reticulocyte proteins for improved detection of recombinant human erythropoietin(rhEPO)abuse[J].Am J Hematol,2021,96(12):1621-1629.
[8] 郑光毅,薛 痕.罗沙司他与重组人促红细胞生成素治疗肾性贫血的研究进展[J].中国中西医结合肾病杂志,2021,22(7):641-643.
[9] 吴 炜,夏茹楠,孟冰冰,等.基于加权TOPSIS法的罗沙司他在治疗肾性贫血中的合理性评价[J].实用药物与临床,2022,25(7):621-625.
[10] 刘莹莹,刘 磊,李祖海,等.罗沙司他治疗老年维持性血液透析患者肾性贫血的疗效和安全性[J].安徽医学,2022,43(7):747-752.
[11] 郑光毅,薛 痕,陈茂丽,等.罗沙司他治疗促红细胞生成素抵抗的肾性贫血患者6例疗效观察[J].中国中西医结合肾病杂志,2022,23(5):454-456.
[12] 敖利娜,解德琼,唐前容,等.罗沙司他治疗非透析慢性肾脏病患者肾性贫血的疗效观察[J].中华实用诊断与治疗杂志,2021,35(7):732-734.
[13] 中国医师协会肾脏内科医师分会肾性贫血指南工作组.中国肾性贫血诊治临床实践指南[J].中华医学杂志,2021,101(20):1463-1502.
[14] 吴心虹,李泰标,廖秋菊,等.补肾养血祛浊方对肾性贫血大鼠血清及肾组织中性粒细胞明胶酶相关脂质运载蛋白的作用研究[J].陕西中医,2020,41(1):12-15.
[15] 苗畅贤,包 品,阎小璐,等.血液透析分别联合血液透析滤过和血液灌流对患者肾性贫血的影响[J].河北医学,2021,27(5):823-826.
[16] 曾 巧,黎 琦,钟庆荣,等.蔗糖铁联合促红细胞生成素治疗维持性血液透析肾性贫血的疗效观察[J].海南医学,2013,24(23):3457-3459.
[17] 吴海婷,李 航.铁剂在肾性贫血治疗中的临床应用[J].临床药物治疗杂志,2021,19(8):13-17.
[18] 魏善斋,孙 杰,许康春,等.排毒生血汤联合促红细胞生成素治疗肾性贫血的效果观察[J].河北医药,2022,44(22):3427-3429,3433.
[19] 文 彬,谢 敏.补肾生血方联合大剂量促红细胞生成素对老年血液透析患者肾性贫血的治疗效果研究[J].四川中医,2022,40(10):120-123.
[20] 程红娟,魏芝薇,史 慧,等.罗沙司他治疗维持性血液透析患者难治性肾性贫血的疗效观察[J].实用临床医药杂志,2021,25(14):75-77,83.
[21] 成水芹,周婷婷,张志宏,等.罗沙司他治疗腹膜透析肾性贫血的有效性及安全性分析[J].肾脏病与透析肾移植杂志,2021,30(3):222-227.
[22] 蒋飞飞,洪大情,杜亚琴,等.罗沙司他治疗血液透析肾性贫血患者的疗效及安全性观察[J].实用药物与临床,2022,25(11):1008-1011.

相似文献/References:

[1]方修移,吴小冬,潘美娟,等.罗沙司他治疗慢性肾脏病合并肾性贫血临床价值研究[J].陕西医学杂志,2024,(5):666.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.020]
　FANG Xiuyi,WU Xiaodong,PAN Meijuan,et al.Value of roxadustat in the treatment of chronic kidney disease complicated with renal anemia[J].,2024,(7):666.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.020]

更新日期/Last Update: 2023-07-05